Why TheranosticTrials.org?

The leading global platform for radiopharmaceutical & molecular imaging clinical trials

Global Reach

We are uniquely positioned at the heart of Theranostics.

Increasing Awareness

We're dedicated to increasing awareness about Theranostics and it's potential.

Fostering Engagement

We encourage active participation in the Theranostics community.

Building Connections

We connect physicians, clinics, and patients with Theranostic opportunities.

Comprehensive Resources

Access a complete list of cancer Theranostic Trials and educational materials.

Advancing the Field

We collaborate with key opinion leaders to push Theranostics forward.

Our Ultimate Goal

Provide more hope to cancer patients everywhere!


Navigating Tips

Pick Your Path


Stats

radiopharm pipeline

Theranostic Research Report

Source: Oppenheimer & Co. Research

View All


Isotopes

View details about the isotopes used in the trials listed on our site!

Learn more
LUTETIUM-177
Radioisotope: Lu-177
Theranostic Role: Therapeutic Agent & SPECT Imaging
T1/2 (Half-Life): 6.7 Days
Decay Mode: BETA, GAMMA
Energy: Eβeta max 497 keV, Gamma 113-208 keV
Range: In Tissue: 0.25-2mm
Decay Daughters: Hf177
Status: FDA Approvals: PLUVICTO® (2022), LUTATHERA® (2017)
SAMARIUM-153
Radioisotope: Sm153
Theranostic Role: Therapeutic
T1/2 (Half-Life): 1.9 Days
Decay Mode: BETA, GAMMA
Energy: Beta: Max 808 keV Gamma: 103 keV (28%)
Range: 0.6 mm
Decay Daughters: Eu153 (Stable)
Status: FDA Approval: QUADRAMET® (1997)
TECHNETIUM-99m
Radioisotope: Tc-99m
Theranostic Role: SPECT Imaging
T1/2 (Half-Life): 6 Hours
Decay Mode: GAMMA
Energy: 140 keV (89.1%)
Range: N/A
Decay Daughters: Tc99
Status: FDA Approval: First in 1980’s

DI Badge

Distinguished Investigator

A Distinguished Investigator of Theranostics is a level of distinction conferred upon an individual physician who has demonstrated a mastery of conducting novel radioligand therapies and molecular imaging clinical trials.

Geoffrey Johnson, MD

Geoffrey B. Johnson, M.D., Ph.D., is a Professor of Radiology, is board-certified in Radiology and Nuclear Medicine and recently rotated out of an 8-year tenure as Chair of Nuclear Medicine at Mayo Clinic. Under his leadership, Mayo Clinic in Rochester MN has become the largest theranostic center in the world, averaging 40 therapies per week for 2023. Dr. Johnson now serves as Associate Director of the Mayo Clinic Comprehensive Cancer Center (MCCCC) and as Chair of Radiopharmaceutical Therapy. Dr. Johnson is founder and Chief Scientific Officer of Nucleus RadioPharma, a CDMO for radiopharmaceutical development, production, and delivery. Dr. Johnson was the top-recruiting physician in the MCCCC in 2022 and has enrolled over 140 patients on radiopharmaceutical cancer therapy trials in the last 3 years, serving as overall PI and local PI. He also serves as Co-PI on multiple active theranostic trials. Dr. Johnson is a co-inventor of Alpha-PET Double-L.E.T. theranostic technologies, the first of which is now licensed to Perspective Therapeutics. Dr. Johnson served as Medical Director of the Nuclear Medicine Technology Program, Program Director of the Nuclear Radiology Fellowship Program and Chair of PET/MR research and development committee. Dr. Johnson earned his B.S. in chemical engineering at the Massachusetts Institute of Technology, receiving Tau Beta Phi academic honors. He completed his M.D./Ph.D. in the Mayo Medical-Scientist Training Program as the Davis Physician-Scientist Scholar. He completed postdoctoral training in immunology and surgery in the Mayo Graduate School. He went on to complete an internship in internal medicine, a residency in diagnostic radiology and a fellowship in nuclear radiology in Mayo School of Graduate Medical Education. In recognition of his work, Dr. Johnson has received awards and honors, including the Roentgen Resident Research Award and the twice the Honored Educator Award, conferred by the Radiological Society of North America; Physician/Scientist of the Year, conferred by Mayo School of Health Sciences; and the Carman Award for Excellence in Clinical Practice, conferred by the Department of Radiology, Mayo Clinic. Dr. Johnson is active in research and education, garnering more than 30 awards with trainees on projects at national and international meetings. Dr. Johnson’s memberships with 13 professional organizations include the AAI, ACR, ABR, ARRS, RSNA, ASNC, SNMMI and STR.

Read More
See All Investigators

RLT Components

RADIOLIGAND THERAPY (RLT) is a highly effective approach to very accurately locating cancer cells and effectively killing those same cells by delivery various radioisotopes to a specific target that is located on a type of cancer. Some of the Radioisotopes are diagnostic for locating cancers & some therapeutic to treat the cancers.

There are several Components to a RLT that are simply demonstrated in the truck diagram including:

  1. Cancer Targets
  2. Ligand (demonstrated as the Truck GPS set to find a specific Target)
  3. Diagnostic Radioisotopes (demonstrated as light bulbs that light the cancer Targets on a PET scan)
  4. Therapeutic Radioisotopes (demonstrated as bombs that kill cancer cells that express the target with either Alpha or Beta radiation)
  5. Linker (demonstrated as the hitch keeping the Radioisotope attached to the Ligand)
  6. Chelator (demonstrated as the Trailers which keeps the Radioisotope on Target).

To learn more about the specific components being studied today on clinical trials around the world check out the RLT COMPONENTSTab.

View RLT Components

Education

Theranostic Trials

Learn More About How Radiation Works

We know radiation can be scary, but we want to show you how radiation isn't all that it seems and how you interact with radiation every day!

Theranostic Trials

Learn More About How Theranostics Work

Theranostics is a two-pronged approach to diagnosing and treating cancers through the use of radiotracers.

Theranostic Trials

Learn More About Clinical Trials

A clinical trial is a research effort that aims to evaluate the effects of an intervention on the development of a disease.

Theranostic Trials

Dictionary of Theranostic Terms

Theranostic Trials

Learn More About Disparities


banana

Sponsors

blueearthdiagnosticsltdadvancedacceleratorapplicationsbayertelixpharmaceuticalsfusionpharmaceuticalsincclaritypharmaceuticalscuriumpointbiopharmaratiotherapeuticsincartbionorthstarnucleusradiopharmaradiopharmtheranosticsinvenraconvergenttherapeuticsterrapowerisotopesrlsradiopharmacies

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468